BACKGROUND: Data on oseltamivir treatment among hospitalized community-acquired pneumonia (CAP) patients are limited. METHODS: Patients hospitalized with CAP at 6 hospitals during the 2010-2012 influenza seasons were included. We assessed factors associated with oseltamivir treatment using logistic regression. RESULTS: Oseltamivir treatment was provided to 89 of 1627 (5%) children (<18 years) and 143 of 1051 (14%) adults. Among those with positive clinician-ordered influenza tests, 39 of 61 (64%) children and 37 of 48 (77%) adults received oseltamivir. Among children, oseltamivir treatment was associated with hospital A (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.36-4.88), clinician-ordered testing performed (aOR, 2.44; 95% CI, 1.47-5.19), intensive care unit (ICU) admission (aOR, 2.09; 95% CI, 1.27-3.45), and age ≥2 years (aOR, 1.43; 95% CI, 1.16-1.76). Among adults, oseltamivir treatment was associated with clinician-ordered testing performed (aOR, 8.38; 95% CI, 4.64-15.12), hospitals D and E (aOR, 3.46-5.11; 95% CI, 1.75-11.01), Hispanic ethnicity (aOR, 2.06; 95% CI, 1.18-3.59), and ICU admission (aOR, 2.05; 95% CI, 1.34-3.13). CONCLUSIONS: Among patients hospitalized with CAP during influenza season, oseltamivir treatment was moderate overall and associated with clinician-ordered testing, severe illness, and specific hospitals. Increased clinician education is needed to include influenza in the differential diagnosis for hospitalized CAP patients and to test and treat patients empirically if influenza is suspected. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Data on oseltamivir treatment among hospitalized community-acquired pneumonia (CAP) patients are limited. METHODS:Patients hospitalized with CAP at 6 hospitals during the 2010-2012 influenza seasons were included. We assessed factors associated with oseltamivir treatment using logistic regression. RESULTS:Oseltamivir treatment was provided to 89 of 1627 (5%) children (<18 years) and 143 of 1051 (14%) adults. Among those with positive clinician-ordered influenza tests, 39 of 61 (64%) children and 37 of 48 (77%) adults received oseltamivir. Among children, oseltamivir treatment was associated with hospital A (adjusted odds ratio [aOR], 2.76; 95% confidence interval [CI], 1.36-4.88), clinician-ordered testing performed (aOR, 2.44; 95% CI, 1.47-5.19), intensive care unit (ICU) admission (aOR, 2.09; 95% CI, 1.27-3.45), and age ≥2 years (aOR, 1.43; 95% CI, 1.16-1.76). Among adults, oseltamivir treatment was associated with clinician-ordered testing performed (aOR, 8.38; 95% CI, 4.64-15.12), hospitals D and E (aOR, 3.46-5.11; 95% CI, 1.75-11.01), Hispanic ethnicity (aOR, 2.06; 95% CI, 1.18-3.59), and ICU admission (aOR, 2.05; 95% CI, 1.34-3.13). CONCLUSIONS: Among patients hospitalized with CAP during influenza season, oseltamivir treatment was moderate overall and associated with clinician-ordered testing, severe illness, and specific hospitals. Increased clinician education is needed to include influenza in the differential diagnosis for hospitalized CAPpatients and to test and treat patients empirically if influenza is suspected. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Fatimah S Dawood; Sandra S Chaves; Alejandro Pérez; Arthur Reingold; James Meek; Monica M Farley; Patricia Ryan; Ruth Lynfield; Craig Morin; Joan Baumbach; Nancy M Bennett; Shelley Zansky; Ann Thomas; Mary Lou Lindegren; William Schaffner; Lyn Finelli Journal: J Infect Dis Date: 2013-08-28 Impact factor: 5.226
Authors: Angela M Caliendo; David N Gilbert; Christine C Ginocchio; Kimberly E Hanson; Larissa May; Thomas C Quinn; Fred C Tenover; David Alland; Anne J Blaschke; Robert A Bonomo; Karen C Carroll; Mary Jane Ferraro; Lisa R Hirschhorn; W Patrick Joseph; Tobi Karchmer; Ann T MacIntyre; L Barth Reller; Audrey F Jackson Journal: Clin Infect Dis Date: 2013-12 Impact factor: 9.079
Authors: Rosanna W Setse; Gary L Euler; Amparo G Gonzalez-Feliciano; Leah N Bryan; Carolyn Furlow; Cindy M Weinbaum; James A Singleton Journal: MMWR Suppl Date: 2011-01-14
Authors: Fiona Havers; Brendan Flannery; Jessie R Clippard; Manjusha Gaglani; Richard K Zimmerman; Lisa A Jackson; Joshua G Petrie; Huong Q McLean; Mary Patricia Nowalk; Michael L Jackson; Arnold S Monto; Edward A Belongia; Heather F Eng; Lois Lamerato; Angela P Campbell; Alicia M Fry Journal: Clin Infect Dis Date: 2015-02-25 Impact factor: 9.079
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Scott A Harper; John S Bradley; Janet A Englund; Thomas M File; Stefan Gravenstein; Frederick G Hayden; Allison J McGeer; Kathleen M Neuzil; Andrew T Pavia; Michael L Tapper; Timothy M Uyeki; Richard K Zimmerman Journal: Clin Infect Dis Date: 2009-04-15 Impact factor: 9.079
Authors: Fiona Havers; Swathi Thaker; Jessie R Clippard; Michael Jackson; Huong Q McLean; Manjusha Gaglani; Arnold S Monto; Richard K Zimmerman; Lisa Jackson; Josh G Petrie; Mary Patricia Nowalk; Krissy K Moehling; Brendan Flannery; Mark G Thompson; Alicia M Fry Journal: Clin Infect Dis Date: 2014-07-16 Impact factor: 9.079
Authors: Mary Louise Lindegren; Marie R Griffin; John V Williams; Kathryn M Edwards; Yuwei Zhu; Ed Mitchel; Alicia M Fry; William Schaffner; H Keipp Talbot Journal: PLoS One Date: 2015-03-25 Impact factor: 3.240
Authors: Stella G Muthuri; Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Tarig S A Al Khuwaitir; Adbullah Al Mamun; Ashish P Anovadiya; Eduardo Azziz-Baumgartner; Clarisa Báez; Matteo Bassetti; Bojana Beovic; Barbara Bertisch; Isabelle Bonmarin; Robert Booy; Victor H Borja-Aburto; Heinz Burgmann; Bin Cao; Jordi Carratala; Justin T Denholm; Samuel R Dominguez; Pericles A D Duarte; Gal Dubnov-Raz; Marcela Echavarria; Sergio Fanella; Zhancheng Gao; Patrick Gérardin; Maddalena Giannella; Sophie Gubbels; Jethro Herberg; Anjarath L Higuera Iglesias; Peter H Hoger; Xiaoyun Hu; Quazi T Islam; Mirela F Jiménez; Amr Kandeel; Gerben Keijzers; Hossein Khalili; Marian Knight; Koichiro Kudo; Gabriela Kusznierz; Ilija Kuzman; Arthur M C Kwan; Idriss Lahlou Amine; Eduard Langenegger; Kamran B Lankarani; Yee-Sin Leo; Rita Linko; Pei Liu; Faris Madanat; Elga Mayo-Montero; Allison McGeer; Ziad Memish; Gokhan Metan; Auksė Mickiene; Dragan Mikić; Kristin G I Mohn; Ahmadreza Moradi; Pagbajabyn Nymadawa; Maria E Oliva; Mehpare Ozkan; Dhruv Parekh; Mical Paul; Fernando P Polack; Barbara A Rath; Alejandro H Rodríguez; Elena B Sarrouf; Anna C Seale; Bunyamin Sertogullarindan; Marilda M Siqueira; Joanna Skręt-Magierło; Frank Stephan; Ewa Talarek; Julian W Tang; Kelvin K W To; Antoni Torres; Selda H Törün; Dat Tran; Timothy M Uyeki; Annelies Van Zwol; Wendy Vaudry; Tjasa Vidmar; Renata T C Yokota; Paul Zarogoulidis; Jonathan S Nguyen-Van-Tam Journal: Lancet Respir Med Date: 2014-03-19 Impact factor: 30.700
Authors: Florian Krammer; Gavin J D Smith; Ron A M Fouchier; Malik Peiris; Katherine Kedzierska; Peter C Doherty; Peter Palese; Megan L Shaw; John Treanor; Robert G Webster; Adolfo García-Sastre Journal: Nat Rev Dis Primers Date: 2018-06-28 Impact factor: 52.329